Founder, Chairman and CEO of Abogen Biosciences
Company website: www.abogenbio.com
Dr. Bo Ying is the founder, chairman and CEO of Abogen, a clinical-stage biotech company focused on delivering transformative medicines through RNA innovation. Since itselfestablishment in 2019, Abogen has quickly become an industry leader in mRNA therapeutics globally and was rated as one of the top 500 companies in China by Hurun.
Dr. Bo Ying is a widely recognized scientist with almost 20 years of experience in the pharmaceutical industry. At Abogen, he led the team that successfully advanced ABO1108 from IND clearance into Phase III clinical trials, making it the world’s first lyophilized mRNA shingles vaccine to reach this critical clinical stage. Prior to founding Abogen, he had held various roles in leading biopharmaceutical companies in Boston including Dicerna (an siRNA company acquired by Novo Nordisk in 2023), Moderna Therapeutics and Trucode Gene Repair (PNA-based gene editing), and he has led teams in formulation research, process development, technology transfer and manufacturing for both siRNA and mRNA drugs.
Dr. Bo Ying has a bachelor’s degree from Fudan University in China and a Ph.D. from Northeastern University in Boston. His work has been published in top peer-reviewed journals such as Cell, Lancet Microbe, Cell Research, and he is the inventor of over 150 patents and patent applications.
Representative Publications
[1] Chen GL, Li XF, Dai XH, Li N, Cheng ML, Huang Z, Shen J, Ge YH, Shen ZW, Deng YQ, Yang SY, Zhao H, Zhang NN, Zhang YF, Wei L, Wu KQ, Zhu MF, Peng CG, Jiang Q, Cao SC, Li YH, Zhao DH, Wu XH, Ni L, Shen HH, Dong C, Ying B, Sheng GP, Qin CF, Gao HN, Li LJ. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomized, double-blind, placebo-controlled, phase 1 trial. Lancet Microbe. 2022 Mar;3(3):e193-e202.
[2] Zhang NN, Zhang RR, Zhang YF, Ji K, Xiong XC, Qin QS, Gao P, Lu XS, Zhou HY, Song HF, Ying B, Qin CF. Rapid development of an updated mRNA vaccine against the SARS-CoV-2 Omicron variant. Cell Res. 2022 Apr;32(4):401-403.
[3] Deng YQ, Zhang NN, Zhang YF, Zhong X, Xu S, Qiu HY, Wang TC, Zhao H, Zhou C, Zu SL, Chen Q, Cao TS, Ye Q, Chi H, Duan XH, Lin DD, Zhang XJ, Xie LZ, Gao YW, Ying B, Qin CF. Lipid nanoparticle-encapsulated mRNA antibody provides long-term protection against SARS-CoV-2 in mice and hamsters. Cell Res. 2022 Apr;32(4):375-382.
[4] Zhao H, Zhang NN, Hannawi S, Zhu AR, Xiong XC, Huang YJ, Yu DD, Chen CJ, Dai J, Abuquta A, Ying B, Zhao JC, Qin CF. Neutralization of Omicron XBB.1 by booster vaccination with BA.4/5 monovalent mRNA vaccine. Cell Discov. 2024 Jan 9;10(1):7.
[5] Hannawi S, Wu XH, Villalobos REV, Burhan E, Borra MDL, Gupta RK, Aquitania GP, Ang BWC, Zabat GMA, Roa CC Jr, Zoleta-De Jesus L, Yu DD, Wang M, Wu Y, Song WJ, Ying B, Qin CF. Efficacy, immunogenicity, and safety of a monovalent mRNA vaccine, ABO1020, in adults: A randomized, double-blind, placebo-controlled, phase 3 trial. Med. 2024 Oct 11;5(10):1282-1292.e3.
[6] Chi H, Zhao SQ, Liu YP, Xiong XC, Zhong X, Suo XX, Huang XY, Yue C, Zhang JJ, Cong Z, Li N, Du FX, Chen T, Ma JR, Wang L, Ying B, Deng YQ, Yin JY, Wang X, Xue J, Qin CF. Efficacy and safety of an mRNA encoding neutralizing antibody against SARS-CoV-2 in non-human primates. Sci Bull (Beijing). 2025 Sep 30;70(18):2948-2952.
[7] Huang YJ, Li L, Yang G, Ma W, Wang Q, Yan XL, Ye Q, Huang XY, Li K, Lv L, Wu XY, Zhang K, Zhou J, Chen X, Lin HS, Xu J, Zhou XT, Lin ZR, Zhong X, Ying B, Wang Y, Kang BH, Qin CF. Pan-membrane pyroptosis of liver induced by gasdermin-encoding mRNAs. Natl Sci Rev. 2025 Oct 21;13(3):nwaf452.
[8] Ren Q, Zhao X, Zhou L, Ye R, Chen L, Ren K, Piao X, Zhou Y, Qi Y, Chan KC, Cao L, Du L, Gao P, Ying B, Deng C, Meng F, Zhou F, Xu C, Zhong Z. Polymer-mRNA complexes for monocyte-trafficked, lymph node-targeted cancer vaccination. Nat Biomed Eng. 2026.
